<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38106559</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-5370</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>EClinicalMedicine</Title><ISOAbbreviation>EClinicalMedicine</ISOAbbreviation></Journal><ArticleTitle>Long-term symptom profiles after COVID-19 <i>vs</i> other acute respiratory infections: an analysis of data from the COVIDENCE UK study.</ArticleTitle><Pagination><StartPage>102251</StartPage><MedlinePgn>102251</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102251</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eclinm.2023.102251</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Long COVID is a well recognised, if heterogeneous, entity. Acute respiratory infections (ARIs) due to other pathogens may cause long-term symptoms, but few studies compare post-acute sequelae between SARS-CoV-2 and other ARIs. We aimed to compare symptom profiles between people with previous SARS-CoV-2 infection, people with previous non-COVID-19 ARIs, and contemporaneous controls, and to identify clusters of long-term symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">COVIDENCE UK is a prospective, population-based UK study of ARIs in adults. We analysed data for 16&#xa0;potential long COVID symptoms and health-related quality of life (HRQoL), reported between January 21 and February 15, 2021, by participants unvaccinated against SARS-CoV-2. We classified participants as having previous SARS-CoV-2 infection or previous non-COVID-19 ARI (&#x2265;4 weeks prior) or no reported ARI. We compared symptoms by infection status using logistic and fractional regression, and identified symptom clusters using latent class analysis (LCA). This study is registered with ClinicalTrials.gov, NCT04330599.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">We included 10,171 participants (1311 [12.9%] with SARS-CoV-2 infection, 472 [4.6%] with non-COVID-19 ARI). Both types of infection were associated with increased prevalence/severity of most symptoms and decreased HRQoL compared with no infection. Participants with SARS-CoV-2 infection had increased odds of problems with taste/smell (odds ratio 19.74, 95% CI 10.53-37.00) and lightheadedness or dizziness (1.74, 1.18-2.56) compared with participants with non-COVID-19 ARIs. Separate LCA models identified three symptom severity groups for each infection type. In the most severe groups (representing 22% of participants for both SARS-CoV-2 and non-COVID-19 ARI), SARS-CoV-2 infection presented with a higher probability of problems with taste/smell (probability 0.41 <i>vs</i> 0.04), hair loss (0.25 <i>vs</i> 0.16), unusual sweating (0.38 <i>vs</i> 0.25), unusual racing of the heart (0.43 <i>vs</i> 0.33), and memory problems (0.70 <i>vs</i> 0.55) than non-COVID-19 ARI.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">Both SARS-CoV-2 and non-COVID-19 ARIs are associated with a wide range of symptoms more than 4 weeks after the acute infection. Research on post-acute sequelae of ARIs should extend from SARS-CoV-2 to include other pathogens.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">Barts Charity.</AbstractText><CopyrightInformation>&#xa9; 2023 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vivaldi</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfeffer</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talaei</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basera</LastName><ForeName>Tariro Jayson</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaheen</LastName><ForeName>Seif O</ForeName><Initials>SO</Initials><AffiliationInfo><Affiliation>Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martineau</LastName><ForeName>Adrian R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Asthma UK Centre for Applied Research, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04330599</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EClinicalMedicine</MedlineTA><NlmUniqueID>101733727</NlmUniqueID><ISSNLinking>2589-5370</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute respiratory infections</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>PEP declares grants paid to their institution from the National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI). The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>18</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38106559</ArticleId><ArticleId IdType="pmc">PMC10721552</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2023.102251</ArticleId><ArticleId IdType="pii">S2589-5370(23)00428-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>NICE . National Institute for Health and Care Excellence; London: 2022. National Institute for Health and Care Excellence: clinical guidelines. COVID-19 rapid guideline: managing the long-term effects of COVID-19.</Citation></Reference><Reference><Citation>Evans R.A., Leavy O.C., Richardson M., et al. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10:761&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber N.H., Kohn J.N., Ogan W.S., et al. Deep dive into the long haul: analysis of symptom clusters and risk factors for post-acute sequelae of COVID-19 to inform clinical care. Int J Environ Res Public Health. 2022;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9778884</ArticleId><ArticleId IdType="pubmed">36554723</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics . Office for National Statistics; London: 2023. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 30 March 2023.</Citation></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns Hopkins University  . 2021. Coronavirus resource center.https://coronavirus.jhu.edu/</Citation></Reference><Reference><Citation>Narasimhan H., Wu Y., Goplen N.P., Sun J. Immune determinants of chronic sequelae after respiratory viral infection. Sci Immunol. 2022;7</Citation><ArticleIdList><ArticleId IdType="pubmed">35857581</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Sullivan O. Long-term sequelae following previous coronavirus epidemics. Clin Med. 2021;21:e68&#x2013;e70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7850177</ArticleId><ArticleId IdType="pubmed">33144403</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J., Jansari V., Hornig M., Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28:911&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B., Sudry T., Flaks-Manov N., et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023;380</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for Health Improvement and Disparities . Office for Health Improvement and Disparities; London: 2022. COVID-19 mental health and wellbeing surveillance: report.</Citation></Reference><Reference><Citation>Holt H., Relton C., Talaei M., et al. Cohort profile: longitudinal population-based study of COVID-19 in UK adults (COVIDENCE UK) Int J Epidemiol. 2022;52(1):e46&#x2013;e56. doi: 10.1093/ije/dyac189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyac189</ArticleId><ArticleId IdType="pmc">PMC9620716</ArticleId><ArticleId IdType="pubmed">36174228</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C., Valdes A.M., Freidin M.B., et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med. 2020;26:1037&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7751267</ArticleId><ArticleId IdType="pubmed">32393804</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson G.G., Dowling H.F., Spiesman I.G., Boand A.V. Transmission of the common cold to volunteers under controlled conditions. I. The common cold as a clinical entity. AMA Arch Intern Med. 1958;101:267&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">13497324</ArticleId></ArticleIdList></Reference><Reference><Citation>Macfarlane J., Holmes W., Gard P., et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax. 2001;56:109&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1746009</ArticleId><ArticleId IdType="pubmed">11209098</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillonel J., Laperche S. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT) Euro Surveill. 2005;10:5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15735313</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolliffe D.A., Holt H., Greenig M., et al. Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT) BMJ. 2022;378</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449358</ArticleId><ArticleId IdType="pubmed">36215226</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Research and Innovation  . 2022. MRC dyspnoea scale.https://www.ukri.org/councils/mrc/facilities-and-resources/find-an-mrc-facility-or-resource/mrc-dyspnoea-scale/</Citation></Reference><Reference><Citation>Kroenke K., Spitzer R.L., Williams J.B., L&#xf6;we B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009;50:613&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">19996233</ArticleId></ArticleIdList></Reference><Reference><Citation>Yellen S.B., Cella D.F., Webster K., Blendowski C., Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J&#xa0;Pain Symptom Manage. 1997;13:63&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">9095563</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin R., de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">11491192</ArticleId></ArticleIdList></Reference><Reference><Citation>Brant R. Assessing proportionality in the proportional odds model for ordinal logistic regression. Biometrics. 1990;46:1171&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">2085632</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams R. Generalized ordered logit/partial proportional odds models for ordinal dependent variables. Stata J. 2006;6:58&#x2013;82.</Citation></Reference><Reference><Citation>Lacy M.G. An explained variation measure for ordinal response models with comparisons to other ordinal R2 measures. Sociol Methods Res. 2006;34:469&#x2013;520.</Citation></Reference><Reference><Citation>Papke L.E., Wooldridge J.M. Econometric methods for fractional response variables with an application to 401: plan participation rates. J&#xa0;Appl Econ. 1996;11:619&#x2013;632.</Citation></Reference><Reference><Citation>Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J&#xa0;R Stat Soc. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Nylund-Gibson K., Choi A.Y. Ten frequently asked questions about latent class analysis. Transl Issues Psychol Sci. 2018;4:440&#x2013;461.</Citation></Reference><Reference><Citation>Vermunt J.K., Magidson J. How to perform three-step latent class analysis in the presence of measurement non-invariance or differential item functioning. Struct Equ Model. 2021;28:356&#x2013;364.</Citation></Reference><Reference><Citation>Szende A., Oppe M., Devlin N., editors. EQ-5D value sets: inventory, comparative review and user guide. Springer; Dordrecht, the Netherlands: 2007.</Citation></Reference><Reference><Citation>Pustake M., Tambolkar I., Giri P., Gandhi C. SARS, MERS and CoVID-19: an overview and comparison of clinical, laboratory and radiological features. J&#xa0;Family Med Prim Care. 2022;11:10&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8930171</ArticleId><ArticleId IdType="pubmed">35309670</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschenberger M., Hunszinger V., Sparrer K.M.J. Implications of innate immunity in post-acute sequelae of non-persistent viral infections. Cells. 2021;10:2134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8391718</ArticleId><ArticleId IdType="pubmed">34440903</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Luciano S., Geddes J.R., Husain M., Harrison P.J. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Baskett W.I., Qureshi A.I., Shyu D., Armer J.M., Shyu C.R. COVID-specific long-term sequelae in comparison to common viral respiratory infections: an analysis of 17.487 infected adult patients. Open Forum Infect Dis. 2023;10:ofac683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9846186</ArticleId><ArticleId IdType="pubmed">36686632</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Liu X., Zhou Y., et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021;9:747&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099316</ArticleId><ArticleId IdType="pubmed">33964245</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Yao Q., Gu X., et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans R.A., McAuley H., Harrison E.M., et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9:1275&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M., Elliott J., Chadeau-Hyam M., et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022;13:1957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y., Deng J., Liu Q., Du M., Liu M., Liu J. Long-term consequences of asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. Int J Environ Res Public Health. 2023;20:1613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9863678</ArticleId><ArticleId IdType="pubmed">36674367</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A.J., MacKenna B., Inglesby P., et al. Clinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY. Br J Gen Pract. 2021;71:e806&#x2013;e814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8340730</ArticleId><ArticleId IdType="pubmed">34340970</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Geddes J.R., Husain M., Luciano S., Harrison P.J. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese J.T., Blau H., Casiraghi E., et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. EBioMedicine. 2023;87</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9769411</ArticleId><ArticleId IdType="pubmed">36563487</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M., Parkin A., Makower S., Greenwood D.C. Post-COVID syndrome symptoms, functional disability, and clinical severity phenotypes in hospitalized and nonhospitalized individuals: a cross-sectional evaluation from a community COVID rehabilitation service. J&#xa0;Med Virol. 2022;94:1419&#x2013;1427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8661751</ArticleId><ArticleId IdType="pubmed">34783052</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowyer R.C.E., Huggins C., Toms R., et al. Characterising patterns of COVID-19 and long COVID symptoms: evidence from nine UK longitudinal studies. Eur J Epidemiol. 2023;38:199&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9860244</ArticleId><ArticleId IdType="pubmed">36680646</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Kelly J.D., Lu S., et al. Persistence, magnitude, and patterns of postacute symptoms and quality of life following onset of SARS-CoV-2 infection: cohort description and approaches for measurement. Open Forum Infect Dis. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755302</ArticleId><ArticleId IdType="pubmed">35106317</ArticleId></ArticleIdList></Reference><Reference><Citation>Talaei M., Faustini S., Holt H., et al. Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK) BMC Med. 2022;20:87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8860623</ArticleId><ArticleId IdType="pubmed">35189888</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas D.R., Fina L.H., Adamson J.P., et al. Social, demographic and behavioural determinants of SARS-CoV-2 infection: a case-control study carried out during mass community testing of asymptomatic individuals in South Wales, December 2020. Epidemiol Infect. 2022;150</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9203360</ArticleId><ArticleId IdType="pubmed">35535456</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinnes J., Sharma P., Berhane S., et al. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2022;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9305720</ArticleId><ArticleId IdType="pubmed">35866452</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Sagar R. A&#xa0;critical look at online survey or questionnaire-based research studies during COVID-19. Asian J Psychiatr. 2021;65</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8426323</ArticleId><ArticleId IdType="pubmed">34534919</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>